×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HOOK – hookipa pharma inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HOOK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
08:05 am
hook
Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at JMP Securities from $24.00 to $7.00. They now have a "market outperform" rating on the stock.
High
Report
Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at JMP Securities from $24.00 to $7.00. They now have a "market outperform" rating on the stock.
11/15
11:23 am
hook
Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at Royal Bank of Canada from $50.00 to $48.00. They now have an "outperform" rating on the stock.
Medium
Report
Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at Royal Bank of Canada from $50.00 to $48.00. They now have an "outperform" rating on the stock.
11/15
05:31 am
hook
HOOKIPA Pharma GAAP EPS of -$1.10, revenue of $4.7M [Seeking Alpha]
Medium
Report
HOOKIPA Pharma GAAP EPS of -$1.10, revenue of $4.7M [Seeking Alpha]
11/14
04:17 pm
hook
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates [Yahoo! Finance]
Medium
Report
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates [Yahoo! Finance]
11/14
04:05 pm
hook
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
Medium
Report
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
11/11
04:05 pm
hook
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
Low
Report
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
10/31
09:20 am
hook
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 [Yahoo! Finance]
Low
Report
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 [Yahoo! Finance]
10/31
09:17 am
hook
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
Low
Report
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
11/21
07:26 am
Maintains
Market Outperform
Market Outperform
JMP Securities
High
Report
-18.3%
11/21
07:26 am
Maintains
Market Outperform
Market Outperform
JMP Securities
High
Report
-18.3%
Date
Time
Symbol
Headline
Impact
11/20
04:09 pm
hook
Form 8-K HOOKIPA Pharma Inc. For: Nov 18
Medium
Report
Form 8-K HOOKIPA Pharma Inc. For: Nov 18
11/14
06:07 pm
hook
Form SC 13G/A HOOKIPA Pharma Inc. Filed by: EcoR1 Capital, LLC
High
Report
Form SC 13G/A HOOKIPA Pharma Inc. Filed by: EcoR1 Capital, LLC
11/14
04:11 pm
hook
Form 10-Q HOOKIPA Pharma Inc. For: Sep 30
Medium
Report
Form 10-Q HOOKIPA Pharma Inc. For: Sep 30
11/14
04:09 pm
hook
Form 8-K HOOKIPA Pharma Inc. For: Nov 14
Medium
Report
Form 8-K HOOKIPA Pharma Inc. For: Nov 14
8/30
08:05 am
hook
Form 8-K HOOKIPA Pharma Inc. For: Aug 27
Low
Report
Form 8-K HOOKIPA Pharma Inc. For: Aug 27
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
Hookipa Pharma Inc (NASDAQ: HOOK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
17.8%
7/11 HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers 16.0%
12/23 Form 4 HOOKIPA Pharma Inc. For: Dec 19 Filed by: Matushansky Igor 14.9%
1/23 2 Small-Cap Biotech Stocks to Watch in 2020 [The Motley Fool] 14.5%
3/19 Form S-8 HOOKIPA Pharma Inc. 11.7%
7/17 Hookipa Pharma Inc (NASDAQ: HOOK) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 10.8%
8/29 HOOKIPA Pharma to Present at Upcoming Investor Conferences in September 9.4%
10/15 Hookipa Pharma Inc (NASDAQ: HOOK) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.0%
4/24 Form 4 HOOKIPA Pharma Inc. For: Apr 20 Filed by: Kandera Reinhard 8.7%
11/13 Hookipa Pharma Inc (NASDAQ: HOOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock. 6.8%
7/11 HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers 16.0%
12/23 Form 4 HOOKIPA Pharma Inc. For: Dec 19 Filed by: Matushansky Igor 14.9%
1/23 2 Small-Cap Biotech Stocks to Watch in 2020 [The Motley Fool] 14.5%
3/19 Form S-8 HOOKIPA Pharma Inc. 11.7%
7/17 Hookipa Pharma Inc (NASDAQ: HOOK) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 10.8%
8/29 HOOKIPA Pharma to Present at Upcoming Investor Conferences in September 9.4%
10/15 Hookipa Pharma Inc (NASDAQ: HOOK) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.0%
4/24 Form 4 HOOKIPA Pharma Inc. For: Apr 20 Filed by: Kandera Reinhard 8.7%
11/13 Hookipa Pharma Inc (NASDAQ: HOOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock. 6.8%
TOP News Decliners
5/20
HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent Business Highlights
-12.9%
7/11 Hookipa Pharma jumps 40% after FDA approval of clinical tests [MarketWatch] -12.2%
3/19 Q4/2019 12/31/2019 EPS -0.400 ZacksConsensus -0.430 ActVsEst 0.030 - Beat -10.5%
3/11 Hookipa Pharma Inc (NASDAQ: HOOK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.7%
3/20 Hookipa Pharma Inc (NASDAQ: HOOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.25 price target on the stock. -8.9%
11/14 Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at Bank of America Corp from $17.00 to $14.00. They now have a "buy" rating on the stock. -6.9%
4/21 HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases -5.6%
11/4 HOOKIPA Pharma To Report Third Quarter 2019 Financial Results on November 12, 2019 -5.5%
10/1 Hookipa Pharma Inc (NASDAQ: HOOK) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.7%
3/10 HOOKIPA Pharma To Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 19, 2020 -4.4%
7/11 Hookipa Pharma jumps 40% after FDA approval of clinical tests [MarketWatch] -12.2%
3/19 Q4/2019 12/31/2019 EPS -0.400 ZacksConsensus -0.430 ActVsEst 0.030 - Beat -10.5%
3/11 Hookipa Pharma Inc (NASDAQ: HOOK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.7%
3/20 Hookipa Pharma Inc (NASDAQ: HOOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.25 price target on the stock. -8.9%
11/14 Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at Bank of America Corp from $17.00 to $14.00. They now have a "buy" rating on the stock. -6.9%
4/21 HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases -5.6%
11/4 HOOKIPA Pharma To Report Third Quarter 2019 Financial Results on November 12, 2019 -5.5%
10/1 Hookipa Pharma Inc (NASDAQ: HOOK) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.7%
3/10 HOOKIPA Pharma To Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 19, 2020 -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: